Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag ADR (OP:BAYRY)

14.00 -0.27 (-1.91%)

Streaming Delayed Price Updated: 10:54 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗

July 08, 2024

Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.

Via InvestorPlace

3 Small-Cap Stocks With Explosive 2X Growth Potential ↗

July 08, 2024

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.

Via InvestorPlace

Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M ↗

June 05, 2024

Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation.

Via Benzinga

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership ↗

June 01, 2024

Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in...

Via Talk Markets

European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday? ↗

May 27, 2024

European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola.

Via Benzinga

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗

May 24, 2024

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

Via Benzinga

Topics Data Breach

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval ↗

May 17, 2024

Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.

Via Benzinga

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗

May 16, 2024

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...

Via Benzinga

BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024 ↗

May 14, 2024

BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch ↗

May 10, 2024

Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with...

Via Benzinga

Topics Artificial Intelligence

Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned ↗

May 02, 2024

Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs...

Via Benzinga

Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades' ↗

April 10, 2024

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is

Via Benzinga

Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists ↗

April 09, 2024

Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses.

Via Benzinga

Topics Artificial Intelligence

Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds ↗

April 05, 2024

Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from...

Via Benzinga

Topics Bonds

Bayer-Backed Boundless Bio Falls After IPO ↗

March 31, 2024

Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company.

Via Talk Markets

Dyadic Intl. Inc. (NASDAQ: DYAI) Potential Strategic Alliances with Future of Foods Boosts Stock as Key Conference Looms

March 19, 2024

Via AB Newswire

Topics Supply Chain

Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant ↗

March 19, 2024

Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential...

Via Benzinga

German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits ↗

March 14, 2024

Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications.

Via Benzinga

Topics Bankruptcy Lawsuit

BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023 ↗

March 05, 2024

BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges ↗

March 05, 2024

Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024.

Via Benzinga

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

What's Going On With BridgeBio Pharma Stock On Monday? ↗

March 04, 2024

BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.

Via Benzinga

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? ↗

March 04, 2024

BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.

Via Investor's Business Daily

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗

March 01, 2024

On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.

Via InvestorPlace

3 Overextended Stocks That Need to Slash Their Dividends ASAP ↗

February 27, 2024

The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big.

Via InvestorPlace

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million ↗

February 11, 2024

I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...

Via Talk Markets

Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial ↗

January 30, 2024

Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.

Via Benzinga

Topics Lawsuit

Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout ↗

January 29, 2024

"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.

Via Benzinga

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.